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Dimorphic fungi are agents of systemic mycoses associated with significant mor-
bidity and frequent lethality in the Americas. Among the pathogenic species are 
Paracoccidioides brasiliensis and Paracoccidioides lutzii, which predominate in South 
America; Histoplasma capsulatum, Coccidioides posadasii, and Coccidioides immitis, 
and the Sporothrix spp. complex are other important pathogens. Associated with 
dimorphic fungi other important infections are caused by yeast such as Candida spp. 
and Cryptococcus spp. or mold such as Aspergillus spp., which are also fungal agents 
of deadly infections. Nowadays, the actual tendency of therapy is the development of a 
pan-fungal vaccine. This is, however, not easy because of the complexity of eukaryotic 
cells and the particularities of different species and isolates. Albeit there are several exper-
imental vaccines being studied, we will focus mainly on peptide vaccines or epitopes of 
T-cell receptors inducing protective fungal responses. These peptides can be carried by 
antibody inducing β-(1,3)-glucan oligo or polysaccharides, or be mixed with them for 
administration. The present review discusses the efficacy of linear peptide epitopes in 
the context of antifungal immunization and vaccine proposition.
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SYSTeMiC FUNGAL iNFeCTiONS AND CURReNT TReATMeNT:  
A SHORT iNTRODUCTiON
Distinct groups of fungi can cause systemic mycoses: geographically delimitated thermal-dimorphic 
fungi, classical yeast such as Cryptococcus spp. and Candida spp., or molds like Aspergillus spp., 
Fusarium spp., and Penicillium spp.
Thermal-dimorphic fungi are a group of ascomycetes endemic in certain regions, agents of the 
most common diseases, such as paracoccidioidomycosis, occurring in the vast area from south 
Mexico to the north of Argentina; coccidioidomycosis in the Americas with particular incidence 
in the USA (California, Texas, Utah, New Mexico, Arizona, and Nevada), Mexico, Colombia, 
Venezuela, northeast of Brazil, and north of Argentina; North American blastomycosis, with high 
incidence in Canada, eastern USA, sporadic cases in Argentina, and endemic areas in middle and 
eastern Africa; histoplasmosis, found in the Americas, Southeast Asia, and Africa; and the Sporothrix 
schenckii complex with worldwide distribution (1). These fungi usually present propagules in the 
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soil, vegetal, or animal excrement. The infection usually starts via 
the respiratory route except for sporotrichosis that rarely occurs 
by inhalation of fungal propagules, rather arising from surface 
injuries by fungus-contaminated objects or cat scratches (1).
Most of patients developing Candida spp. and Cryptococcus 
spp. infections are immunodeficient suffering from AIDS, dia-
betes, or have been administered immunosuppressive drugs as 
in organ transplantation procedures, indwelling catheter for a 
short or long time, although primary infections can also occur 
without association with other conditions (2, 3). Aspergillus 
fumigatus, Fusarium spp., and Penicillium spp. can cause differ-
ent types of infection. Patients undergoing hematopoietic stem 
cell transplantation for treatment of hematological malignancy 
have considerable risk of developing fatal fungal infection (4, 5). 
Whereas infection by Candida spp. occurs mainly by endogenous 
yeast, this is not an exclusive pathway. Infections by Cryptococcus 
spp., A. fumigatus, Fusarium spp., and Penicillium spp. occur by 
inhalation of fungal propagules (2–5).
There is no trustworthy quantitation of people infected 
by systemic mycosis in the World; however, Brown et  al. (6) 
estimated that more than 2,050,000 people yearly infected 
with the 10 most significant invasive fungal agents/mycoses 
including Aspergillus, Candida, Cryptococcus, mucormycosis, 
Pneumocystis, Blastomyces, Coccidioides, Histoplasma, Penicillium, 
and Paracoccidioides (6).
There are few groups of antifungal drugs effective in the treat-
ment of systemic fungal disease. Most of them belong to four 
classes: polyenes, azoles, echinocandins, and pyrimidine (7). 
Other antimicrobial drugs also have antifungal action such as 
trimethoprim-sulfamethoxazole that is used with relative success 
in the treatment of patients with paracoccidioidomycosis (8). 
Treatment and the option for antifungal drugs depend on the 
severity of the disease and time of use (9).
There are many reports on drug resistance in systemic 
fungal  infections involving almost all classes of antimicrobial 
drugs. In paracoccidioidomycosis, resistance to ketoconazole 
and trimethoprim-sulfamethoxazole may be related to the agent 
species (Paracoccidioides brasiliensis or Paracoccidioides lutzii) 
[reviewed in Ref. (9)] or the melanization process, which enhances 
the resistance of yeast cells to amphotericin B (10). The biofilm 
formation in Candida spp. can enhance resistance of yeast cells 
to antifungal drugs (11, 12), and the Candida albicans biofilm is 
intrinsically resistant to the host immune system [reviewed in 
Ref. (12)]. Such resistance appears to be multifactorial involv-
ing conventional resistance mechanisms as the increased efflux 
pump, and mechanisms specific to the biofilm as the production 
of an extracellular matrix containing β-glucan and extracelluar 
DNA [reviewed in Ref. (11)]. The resistance to azoles by efflux 
pump proteins in Candida albicans may involve overexpression 
of Cdr1p (ATP-binding cassette) and CaMdr1p (major facilitator 
superfamily) as reviewed in Ref. (13).
Due to the increasing resistance, several groups of research-
ers focus on safer and effective new antifungal compounds. 
Authors have isolated Paracoccidioides spp. (14) and Candida 
(15) susceptible to curcumin. The use of ajoene derived from 
garlic with antifungal activity against Paracoccidioides brasiliensis 
(16), Scedosporium prolificans (17), and dermatophytes (18) has 
also been reported. Antiretroviral protease inhibitors such as 
Saquinavir and Ritonavir have shown inhibitory activity against 
Histoplasma capsulatum (19) and Candida albicans (20). In addi-
tion, several other reports showing the antifungal activities of dif-
ferent compounds with potential use in patients have appeared, 
still without clearance from regulatory institutions.
Generally, the immune system is important to achieve good 
therapeutic results in association with antifungal drugs. The 
status of innate and adaptive immune system plays a central role 
in the protection against foreign pathogens. In contrast to immu-
nocompetent individuals, immunosuppressed patients are much 
more susceptible to fungal infections some of them fatal (21, 22).
The cellular immune system is essential to protect and eliminate 
fungal pathogens; in general, dendritic cells (DCs), macrophages, 
and neutrophils are central in the mechanisms of fungal elimina-
tion. Antigenic peptides are presented to lymphocytes with sub-
sequent eliciting of T-cell and B-cell effective responses (21–24). 
Differentiation of CD4+ T cells along a T-helper (Th) cell type 1 
(Th1) or type 2 (Th2) pathway and development of specific Th 
responses determine host’s susceptibility or resistance to invasive 
fungal infections. A Th1 response is induced by cytokines, such 
as IFN-γ, interleukin (IL)-6, tumor necrosis factor (TNF)-α, and 
IL-12. The main Th2 cytokines are IL-4 and IL-10. IFN-γ activates 
macrophages and increases fungistatic and fungicidal activities. 
Th17 cells and IL-22 are involved in the activation and repair of 
epithelial barriers, and while activated by IL-17 are crucial for 
antifungal defense and control of the NK cells (21–25).
The function of antibody-mediated immunity against fungal 
infections was believed to have little or no role in protection 
against fungal diseases in the past (26). However, since Dromer 
et al. showed that a monoclonal antibody to Cryptococcus neo-
formans was effective against the fungal infection (27), a series 
of protective monoclonal antibodies against medically important 
fungi have been described (26). The protective mechanism of 
antibody-mediated immunity depends on opsonization, Fc 
receptor-dependent ADCC, immunoglobulin subclasses, genetic 
background, status of the cellular immune system, fungal burden, 
amount of patient administered monoclonal antibodies, among 
other characteristics (26).
Antifungal drugs are the basis of systemic mycoses treatment 
in both immunocompetent and immunosuppressed patients. 
However, immunosuppression or anergy may interfere with 
chemotherapy efficiency. Vaccination (therapeutic or prophy-
lactic) may boost the immune system and add to the protective 
effect of antifungal drugs allowing for reduction of the time of 
treatment and prevention of relapse. In this review, we focus 
mainly on vaccines and epitope description.
Paracoccidioides brasiliensis
The major diagnostic antigen of Paracoccidioides brasiliensis is the 
43 kDa glycoprotein (gp43) discovered in 1986 by Puccia et al. 
(28). A detailed description of gp43 was reviewed in Travassos 
et  al. (29). Epitopes in the gp43 are peptide in nature so that 
patients’ sera reacted with the deglycosylated antigen (30). 
Several mAbs were raised to the gp43 and tested either in vivo 
against lung infections by Paracoccidioides brasiliensis or in 
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phagocytosis assays with peritoneal and alveolar macrophages. 
Most mAbs stimulated the phagocytosis of yeast forms (31). MAb 
3E, which was effective both in the reduction of fungal burdens 
in infected animals and in the promotion of phagocytosis, was 
tested for binding to a panel of gp43 internal peptides. The mAb 
3E epitope lied within the sequence NHVRIPIGYWAV shared 
with A. fumigatus, Aspergillus oryzae, and Blumeria graminis 
sequences from β-1,3-glucanases (29).
Other protein antigens eliciting protective antibodies have 
been described but the B-cell epitopes were not characterized. In 
relation to the recently recognized P. lutzii species, the gp43 and 
27 kDa antigens were less expressed in P. lutzii and PS2 genotype 
of Paracoccidioides brasiliensis (32). The gp43 ortholog in P. lutzii 
contains few epitopes in common with the Paracoccidioides bra-
siliensis gp43, contributing to serological diagnostic difficulties in 
patients infected with P. lutzii (33).
The gp43 elicits an IFN-γ-mediated T-CD4+ response, which is 
protective against the lung infection by Paracoccidioides brasilien-
sis. The gp43 was cloned, sequenced, and expressed in bacteria as 
a recombinant fusion protein (34). The amino acid sequence was 
deduced from a 987-bp fragment obtained by PCR amplification. 
Similarities of 56–58% were found with exo-1,3-β-d-glucanases 
of Saccharomyces cerevisiae and Candida albicans. The open-
reading frame was found in a 1,329 bp fragment, encompassing 
two exons and one intron. The gp43 gene encodes 416 amino 
acids with a leader peptide of 35 aa. Epitopes able to elicit 
hypersensitivity in both guinea pigs (35) and humans (36) were 
described. A peptide of 15 amino acids (QTLIAIHTLAIRYAN) 
obtained from a collection of gp43 internal peptides, which was 
also located using DNAStar, Protean analysis Sette algorithm for 
Iad binding peptides (37), contained the T-CD4+ epitope, and was 
called P10 (38). The functional activities of P10 analogs and trun-
cated peptides were studied. Peptides of 12 aa or longer, which is 
the size required for MHC II antigen presentation, were active. 
The sequence HTLAIR is an essential domain of the epitope. 
Gene polymorphism studies showed that the P10 sequence is 
highly conserved in Paracoccidioides brasiliensis isolates (39). In 
contrast, the corresponding sequences of Candida albicans and S 
cerevisiae exo-glucanases differed from P10 (40).
As with the gp43, P10 induces a Th1 lymphocyte response, 
which is protective against the intratracheal (i.t.) infection by 
virulent Paracoccidioides brasiliensis. IFN-γ is a key cytokine 
in this response as it has been shown to activate macrophages 
for increased fungicidal activity against Paracoccidioides bra-
siliensis and Blastomyces dermatitidis (41). It also plays a role 
in the organization of granulomas. Mice deficient in the IFN-γ 
are highly susceptible to Paracoccidioides brasiliensis infection. 
IFN-γ-receptor (but not IFN-α-R and IFN-β-R), IFN-γ, and 
IRF-1 KO mice were 100% killed 3–4 weeks following i.t. infec-
tion with virulent Paracoccidioides brasiliensis. P10 failed to 
protect those KO mice (40).
P10 AS A vACCiNe CANDiDATe
P10 contains the T-CD4+ epitope that is presented by MHC 
II molecules from murine H-2 haptotypes a, b, and d (38). 
The promiscuous nature of P10, if also shown with HLA-DR 
molecules, could represent an important attribute of this 
peptide to be used in a human vaccine to paracoccidioidomy-
cosis. Iwai et al. (42) tested P10 and the analogous peptide gp43 
(180–194), which included an N-terminal lysine and omitted 
the C-terminal asparagine, a glycosylated residue in the gp43. 
Both peptides bound to the nine prevalent HLA-DR molecules 
confirming their ability to be presented by different MHC II 
antigens. Gp43 (180–194) and four other peptides identified 
by TEPITOPE algorithm were recognized by 53 and 32–47%, 
respectively, of patients with treated paracoccidioidomycosis. 
Seventy-four percent of patients recognized a combination 
of five promiscuous gp43 peptides. TEPITOPE scanned 25 
Caucasian HLA-DR antigens with P10 and analogous peptides, 
all containing the HTLAIR core sequence, being predicted to 
bind to 90% of them. The four peptides that were predicted 
to bind to a large number of HLA-DR molecules, in addition to 
Gp43 (180–194), were Gp43 (45–59): IGGWLLLEPWISPSV; 
Gp43 (94–108): TEDDFKNIAAAGLNHV; Gp43 (106–120): 
LNHVRIPIGYWAVNP; and Gp43 (283–298): IDQHVKLACS 
LPHGRL (42). These peptides could be added to P10 or Gp43 
(180–194) in case the single epitope-based vaccine may not be 
powerful enough to induce full protective immunity. Indeed, 
multiple B-cell and T-cell epitopes in a pool or as a multi-epitope 
polypeptide were reported to increase immunogenicity (43, 44).
In the mouse experimental infection, P10 alone exerted an 
efficient antifungal immunity against i.t. infections by virulent 
Paracoccidioides brasiliensis strains (Figure 1). A classical dem-
onstration by histopathology shows murine lung sections from 
i.t.-infected BALB/c mice with large granulomas and numerous 
fungal cells as compared to preserved lung parenchyma, few or 
no detectable granulomas, very few or absence of fungal ele-
ments, in P10 immunized mice (45). Early experiments used 
complete Freund adjuvant as an adjuvant to both gp43 and P10. 
Mayorga et al. (46) showed that mice treated with the cationic 
lipid dioctadecyl-dimethylammonium bromide (DODAB) fol-
lowed in efficiency by bacterial flagellin, both adjuvants to P10, 
were best protected against fungal infection as demonstrated by 
the lowest numbers of viable yeast cells and reduced granuloma 
formation and fibrosis. IFN-γ and TNF-α, in contrast to IL-4 and 
IL-10, were secreted in the lungs of mice immunized with P10 in 
combination with these adjuvants. When combined with antifun-
gal drugs, P10 was protective even in animals submitted to severe 
immune suppression (47). P10 immunization together with itra-
conazole or sulfamethoxazole and trimethoprim chemotherapy 
resulted in 100% survival of infected immunocompromised 
mice, up to 200  days postinfection, whereas untreated anergic 
mice died within 80 days.
P10 is primarily an antigenic peptide that is presented by MHC 
II molecules to induce a Th1 T-CD4+ cell proliferation, which 
exerts an IFN-γ-dependent antifungal protection. Generally, 
T-CD4+ cells confer resistance through secretion of cytokines 
such as IFN-γ, TNF-α, GM-CSF, and IL-17A, which can activate 
neutrophils, macrophages, DCs, and inflammatory monocytes 
for fungal killing and clearance. Activation of B cells leads to the 
secretion of protective antibodies (22, 48).
There is, however, some evidence of an immunomodulatory 
effect of P10 in  vivo, which parallels the biological effects of 
FiGURe 1 | Lung tissue from BALB/c mice infected with Paracoccidioides brasiliensis vaccinated or not with peptide P10. (A) Lung tissue of control 
only infected mice. Bar, 400 μm. (B) Lung tissue of mice infected with Paracoccidioides brasiliensis and vaccinated with P10 in presence of cationic lipid. Bar, 
400 μm. (C) Highly magnified lung tissue of control, only infected mice. Bar, 50 μm. (D) Lung tissue of mice infected with Paracoccidioides brasiliensis and 
vaccinated with P10 in presence of cationic lipid. Bar, 400 μm. Slides were stained with Grocott-Gomori methenamine silver. Pictures were taken using EVOS 
fluorescence microscopy (AMG). The Animal Care and Use Committee of the University of São Paulo approved all in vivo testing.
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isolated immunoglobulin CDRs and fragments of transcrip-
tion factors (49, 50). These short peptides were able to activate 
bone-marrow DCs, which in turn started an immune response 
protective against antigenically unrelated metastatic murine 
melanoma.
A similar effect was observed with the combination of 
P10 and the TLR-5-binding Salmonella typhimurium FliCi 
flagellin (51), using the same metastatic melanoma system. 
Compounds were administered intranasally into C57Bl/6 
mice, challenged intravenous (i.v.) with syngeneic B16F10-
Nex2 murine melanoma cells. A marked reduction in the 
number of pulmonary tumor cell nodules was observed with 
a significant increase in the survival of challenged animals. 
Noticeable immunological responses were the M1 lung mac-
rophages and secretion by lymph node cells and splenocytes of 
IL-12p40 and IFN-γ when they were restimulated with tumor 
antigens.
Therefore, P10 acts not only as a specific Th1 Paracoccidioides 
brasiliensis antigen but also as a non-specific immunomodulatory 
peptide, much like a series of other anti-cancer peptides (49).
Ex vivo P10-primed bone-marrow DCs were administered 
to Paracoccidioides brasiliensis i.t.-infected mice (52). There 
followed a significantly reduced fungal burden and decreased 
pulmonary damage. Increased production of IFN-γ and IL-12 
and reduction in IL-10 and IL-4 compared to the untreated or 
unprimed, DCs-treated mice were obtained. A vaccine, there-
fore, with P10-primed DCs has the potential of rapid protection 
against the development of serious paracoccidioidomycosis in 
infected patients.
P10 MiNi-GeNe THeRAPY
An early plasmid vaccine with a mammalian expression vector 
carrying the gp43 gene induced specific antifungal antibodies 
and a T cell-mediated immune response under the control of the 
CMV promoter (53). The IFN-γ-mediated immune response, 
which was effective against the i.t. infection by Paracoccidioides 
brasiliensis, lasted for at least 6 months after DNA-vaccine admin-
istration. Plasmids with P10 mini-gene insert (pP10) and also with 
IL-12 insert (pIL-12) were later used in an immunoprophylactic 
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protocol and their association completely eliminated the fungal 
elements [colony forming units (CFUs)] in the lungs from i.t.-
infected animals (54). In a therapeutic protocol, empty plasmids 
were inactive and only the combination of both pP10 and pIL-12 
achieved maximal protection using both BALB/c and B10.A 
(susceptible) mouse strains.
In a long-term protocol in which plasmids were administered 
in B10.A susceptible mice, 30 days after infection and the animals 
were sacrificed 6 months after infection, the pP10 vaccine alone 
reduced lung CFUs more than 100-fold and the combination 
of pP10 and pIL-12, virtually eliminated all fungal cells with 
recovery of the lung architecture. These are very encouraging 
results toward the use of gene therapy with P10 DNA insert, 
along with pIL-12 for a long lasting immune protection against 
paracoccidioidomycosis.
The above-described results are a remarkable example 
of effective immune responses elicited by a single epitope 
against a systemic fungal infection. Their complexity, how-
ever, is far from being completely understood. Owing to 
persistent antigen stimulation and active immune response, 
the infection by Paracoccidioides brasiliensis is characterized 
by granuloma formation and fibrosis. Remarkably, the associa-
tion of the cationic lipid (DODAB) and P10 resulted in sig-
nificant reduction of pulmonary fibrosis in animals developing 
paracoccidioidomycosis.
OTHeR AGeNTS OF SYSTeMiC MYCOSeS
Coccidioides immitis and Coccidioides 
posadasii
As with Paracoccidioides brasiliensis, T cell-mediated immunity 
seems to be most important in the protection against Coccidioides 
infection (55–57). High titers of antibodies correlate with poor 
clinical prognosis, although there is evidence showing that a 
specific humoral response can modulate the immune response 
and contribute to host resistance (55–57).
A cell wall associated proline-rich antigen known as antigen 2 
(Ag2) and Ag2/Pra showed to be protective against Coccidioides 
infection using an experimental model (58, 59). A recombinant 
rAg2/Pra protein and a genetic vaccine with AG@/PRA elicited 
protective CD4+ T-cell-mediated response, although the route of 
immunization with both antigens showed some inconsistence 
(59).
Herr et al. (59) showed that Coccidioides posadasii produces 
a homologous proline-rich antigen denominated Prp2, which 
shows 69% protein identity and 86% similarity to Ag2/Pra. 
Protection against intra nasal challenge of C57BL/6 mice was 
verified by subcutaneous vaccination with single bacterially 
expressed homolog, rAg2/Pra or rPrp2 in association with rAg2/
Pra in the presence of the CpG oligodeoxynucleotides adjuvant 
(59). A significant improvement of protective immunity induced 
by vaccination with combined rAg2/Pra and rPrp2 proteins 
was observed when compared to immunization with the single 
recombinant proteins (59).
Peptide libraries from proline-rich Ag2/Pra and Prp2 were 
used for mapping CD4+ T-cell epitope by analysis of the T-cell 
response in an IFN-γ-ELISPOT assay. Six sequences of Ag2/
Pra overlapping peptides (TRLTDFKCHCSKPELPGQIT, HCSK 
PELPGQITPCVEEACP, PIDIPPVDTTAAPEPSETAE, TTAAP 
EPSETAEPTAEPTEE, PTEEPTAEPTAEPTAEPTHE, and PTAE 
PTAEPTHEPTEEPTAV) and three sequences of PrP2 (EKLTD 
FKCHCAKPELPGKIT, DTRTPTQPPSTSPSAPQPTA, and PSTS 
PSAPQPTACI-PKRRRA) induced IFN-γ by CD4+ T cells isolated 
from mice immunized with either rAg2/Pra or rPrp2 (59). Albeit 
some peptides exhibited high similarity in their sequences, cross-
reactions with T cells from either rAg2/Pra or rPrp2-immunized 
mice were not observed. Peptide sequences with high T-cell 
stimulatory response from homologous immunized mice con-
tained one or more TXX’P sequences. The XX residues, however, 
of TXX’P motifs of Ag2/Pra and Prp2 differed (59).
Hurtgen et al. (60) described a strategy for the construction 
and immunological evaluation of a recombinant epitope-based 
vaccine. The use of a computational algorithm (ProPred), which 
identified putative T-cell epitopes predicted to bind promiscu-
ously to human MHC class II molecules, revealed three antigens: 
aspartyl protease (Pep1), alpha-mannosidase (Amn1), and 
phospholipidase B as potential vaccine candidates (60). T-cell 
reactivity of synthetic peptides carrying all predicted epitopes 
was tested by IFN-γ ELISPOT assay.
A single, bacteria-expressed, and recombinant epitope-
based vaccine was constructed with five promiscuous, 
immunodominant T-cell epitopes derived from Pep1 
(MRNSILLAATVLLGCTSAKVHL and HVRALGQKYFGSLP 
SSQQQTV), Amn1 (PAKVDVLLAQSLKLADVLKF and NGLA 
TTGTLVLEWTRLSDIT), and P1b (TPLVVYIPNYPYTTWS 
NIST). The upstream 20-mer peptide had the N-terminal of 
each epitope flanked by Ii-Key fragment (LRMKLPKS), and the 
C  termini in four of the five peptides were flanked by CPGPG 
spacer to avoid processing of junctional epitopes (60).
C57BL/6 mice immunized with the epitope-based vaccine 
admixed with synthetic CpG ODN adjuvant or loaded on 
yeast glucan particles, and then challenged intranasally with 
Coccidioides posadasii, induced an infiltration of active T helper-1 
(Th1), Th2 and Th17 cells, enhanced IFN-γ and IL-17, and 
reduced lung fungal burden with prolonged animal survival (60).
In some infections by dimorphic fungi, even in the absence of 
CD4+ T cells, mice had long-term survival mediated by vaccine-
induced IL-17-producing CD8+ T cells (61). Recombinant 
CD4+ and CD8+ T-cell epitopes joined by non-immunogenic 
linkers were loaded on glucan particles (composed primarily of 
β-1,3-glucan) which delivered the vaccine to APCs. Beta-glucan 
activates the alternative pathway of complement with deposi-
tion of C3 fragments, thus leading to phagocytosis by DCs and 
macrophages mediated by complement receptors and dectin-1. A 
decapeptide (EP67) agonist of active C-terminal region of human 
complement C5a acted as an adjuvant enhancing antigen pres-
entation by macrophages and DCs but not neutrophils due to its 
high affinity for C5a receptors (C5aR/CD88) (61). This adjuvant 
was effective when conjugated with lysine residues on the surface 
of live arthroconidia from the vaccine strain. EP67 directs the 
vaccine to C5aR-bearing macrophages and DCs, inducing phago-
cytosis and antigen presentation. BALB/c mice immunized with 
EP67 conjugated, live vaccine, increased survival and decreased 
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inflammatory pathology, fungal burden, and neutrophils in the 
lungs (62). EP67 conjugated with epitope-based protein vaccines 
may provide an effective mechanism to further augment Th17 
immunity (61). The use of glucan particles as a delivery and 
adjuvant compound as used here to treat coccidiomycosis could 
become in the future an important carrier of peptide antigens 
eliciting protective immune cellular responses, thus following the 
pioneering work in Candida albicans. Coincidently with Candida 
albicans, the cellular response elicited against Coccidioides was 
also characterized by increased Th17 immunity.
Histoplasma capsulatum
Scheckelhoff and Deepe described an immunogenic heat shock 
protein-60 region (F3, fragment 3), which conferred protection 
against experimental Histoplasma infection (63, 64). A T-cell clone 
from C57BL/6 mice expressing Vβ 8.1/8.2+ T cells was generated 
after subcutaneous rHsp60 immunization and was efficacious for 
rHsp60-induced protective effect. TCR analysis showed that a 
subset of Vβ 8.1/8.2+ that produced IFN-γ and reacted with F3, 
shared a common CDR3 sequence, DGGQG (64). It seems that 
a distinct subset of Vβ 8.1/8.2+ T cells is crucial for generating a 
protective response following rHsp60 immunization.
CD4+ T-cell depletion during primary infection by H. capsula-
tum led to animal’s death, whereas lack of CD8+ T cells decreased 
fungal clearance (65). Remarkably, however, CD4+ T cells are 
dispensable in vaccine immunity to H. capsulatum [reviewed in 
Ref. (66)]. In the absence of CD4+ T cells, CD8+ T cells must 
be present exclusively during vaccine induction. Alternatively, 
immune CD8+ T cells generated in wild type mice, in the absence 
of CD4+ T cells, were adoptively transferred to mice infected with 
Blastomyces giving rise to effector cells lowering by 15-fold the 
lung CFU compared to no T cells. In both H. capsulatum and B. 
dermatitidis infections, when CD4+ T cells are absent, CD8+ T 
cells participate as effectors of vaccine immunity against these 
fungi (67). Likely, MHC-I molecules cross-present exogenous 
fungal antigens to vaccine-induced CD8+ T cells. These results 
point to the feasibility of developing vaccines against fungal 
infections in patients with immune deficiencies such as AIDS. 
They also illustrate the plasticity of the immune system adding 
unsuspected functional roles to cells and soluble mediators.
Aspergillus fumigatus
Invasive aspergillosis has significant incidence in immunocom-
promised hosts, with high mortality rate. Ito et al. demonstrated 
that sonication of A. fumigatus hyphae liberated an antigen able 
to protect corticosteroid immunosuppressed mice from invasive 
aspergillosis (68). Subcutaneous vaccination with recombinant 
allergen Asp f3, a 19 kDa protein recognized by antibodies from 
mice exposed intranasally to A. fumigatus conidia, with or without 
TiterMax adjuvant was protective (68). Two T-cell epitopes have 
been identified, and orthologs of Asp f3 have also been found 
in other Aspergillus species, Coccidioides posadasii, Penicillium 
citrinum, Candida albicans, Candida boidinii, S. cerevisiae. Since 
Asp f3 could mediate allergic bronchopulmonary aspergillosis, 
authors focused on eliminating its allergenic property after 
mapping the reactive epitopes. Several truncated forms of Asp f3 
were synthesized and by using mass spectrometric analysis, two 
peptides were identified, 11-mer (PGAFTPVCSAR) and 13-mer 
(HVPEYIEKLPEIR), able to stimulate Asp f3-specific T cells (68).
The protection mediated by Asp f3 was investigated in 
experimentally infected mice. After vaccination, specific Asp f3 
pre-infection IgG titers did no differ in resistant and susceptible 
mice and passive transfer of Asp f3 antibodies did not protect 
immunosuppressed mice from aspergillosis. In fact, the antigen 
is not accessible unless both cell walls and membrane have been 
permeabilized (69). Depletion of CD4+ T cells, however, reduced 
the survival of rAsp f3-vaccinated mice. Transference of purified 
CD4+ T cells from rAsp f3-vaccinated mice into non-vaccinated 
mice conferred protection (69).
Consecutive 5-aa overlapping peptides from Asp f3 (15–168) 
sequence were synthesized. Mice were vaccinated subcutaneously 
with non-allergenic recombinant Asp f3 (15–168)-based vaccine, 
suspended in TiterMax adjuvant. Five weeks after the second 
immunization, mice were immunosuppressed with subcutane-
ous injection of cortisone acetate (2.5  mg) in suspension with 
methylcellulose (0.5%) and Tween 80 (0.1%) for 10 days. Mice 
were then anesthetized and intranasally inoculated with three 
million conidia. Significant protection was observed with such 
rAsp f3 vaccination (69).
Diaz-Arevalo et  al. refined the previous search for immu-
nogenic Asp f3 epitopes (70). T-cell proliferation with a set of 
overlapping synthetic 20-mer peptides was carried out. T cells 
from Asp f3 (15–168)-vaccinated non-infected mice as well as 
vaccinated infected survivors showed proliferative responses to 
the synthetic peptides: VCSARHVPEYIEKLPEIRAK (residues 
60–79) and EIRAKGVDVVAVLAYNDAYV (residues 75–94). 
Sera from vaccinated survivors of experimental A. fumigatus 
challenge and from non-surviving mice were analyzed. Elevated 
titers of IgG to VCSARHVPEYIEKLPEIRAK were found only 
in the surviving group suggesting that the deduced sequence 
contains both a B-cell epitope and a T-cell epitope (70).
Vaccination of a susceptible population to an opportunistic 
disease like invasive aspergillosis was approached by Stevens et al. 
(56). The least immunocompromised patients might be consid-
ered as an initial step. Candidates to immunization could include 
chronic granulomatous disease patients, transplant, leukemics, 
solid tumor at diagnosis, rheumatic or inflammatory bowel, and 
intensive care unit patients. Donors of hematopoietic stem cell 
transplants are also immunization candidates. As mentioned 
above, CD8+ T cells can be used in CD4-deficient hosts, and vac-
cines can be used aiming at stimulating the immune response, 
reducing immunosuppression, or acting synergistically with 
antifungal therapy.
Candida albicans
Invasive candidiasis is often associated with immunosuppression, 
prolonged antibiotic treatment, and anatomical lesions like sur-
gery or venous catheter. A mortality of >30% is observed. Other 
clinical forms of candidiasis such as skin infections, oropharyngeal 
mucosa, and vaginal are most frequent but less severe. Knowledge 
of protective immune responses in candidiasis is thus a major 
aspect to be pursued in the field of systemic mycoses. Bär et al. 
used immunoproteomics to investigate natural T-cell epitopes 
of Candida albicans. The authors identified an MHC II-bound 
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peptide that is recognized by 1/4 of all Candida albicans-specific 
Th cells, a remarkably high frequency of interaction (71).
Four peptides were identified, with overlapping sequences, 
derived from a homologous region of the related adhesins Als1 
and Als3. The longest of the three identified Als1/Als3-derived 
peptides (amino acid residues 236–253) was chosen for further 
analysis, referred to as pALS [sequences, indicating in bold the 
predicted MHC II-binding epitope: KGLNDWNYPVSSESFS(Y)
(T)]. The novel antigenic peptide of Bär et al. has an important 
role in fungal pathogenicity. It is functionally conserved in 
non-albicans Candida species, and most importantly, the 
epitope-specific T cells are not only murine but also human. 
Human memory Th cells responded to peptide stimulation, and 
vaccination of mice with the peptide elicited a T cell-dependent 
anti-candidiasis immune response (71). The pALS peptide of 
Candida albicans, carrying a promiscuous epitope, and eliciting a 
protective antifungal immune response, is functionally similar to 
Paracoccidioides brasiliensis P10, a peptide candidate of a vaccine 
against systemic paracoccidioidomycosis (see above section). 
pALS-specific T cells from the cervical lymph nodes of orally 
infected mice secreted IL-17A, but not IFN-γ or IL-4 (71).
Another methodology was used by Wang et  al. (72), who 
evaluated a hybrid phage as a potential vaccine candidate without 
adjuvant against Candida albicans. The ability of hybrid phage 
displaying epitope SLAQVKYTSASSI to induce an immune 
protective response was studied in a mouse model. Strong cel-
lular and humoral immune responses were induced similar to 
recombinant rSap2 protein immunization. Protection against 
intravenous lethal challenge with Candida albicans was observed 
in BALB/c mice immunized with hybrid phage confirming 
its great potential as a vaccine inducing strong Th1 and Th17 
response without adjuvant (72).
A vaccine that could be effective against Candida albicans 
and a variety of other human pathogenic fungi was proposed by 
Cassone and coworkers (73, 74), based on Laminaria digitata’s 
β-glucan (laminarin). To increase the immunogenicity of the glu-
can, it was conjugated with the diphtheria toxoid CRM197. The 
conjugate was protective against systemic and vaginal Candida 
albicans infections, by eliciting anti-β-glucan antibodies, mainly 
IgG2b. These antibodies bound to and inhibited growth of both 
Candida albicans and A. fumigatus hyphae.
To understand the nature of the epitopes recognized by protec-
tive antibodies to these conjugates, studies were carried out with 
the following compounds, in addition to the laminarin-diphthe-
ria toxoid (CRM197) conjugate, which was protective against 
fungal infections in mice (75): natural curdlan (Curd)-CRM197; 
linear 15-mer-CRM197 or 1,6-branched-17-mer-CRM197 
β-(1,3)-glucan-derived oligosaccharides. Anti-β-(1,3)-glucan 
IgG antibodies were specifically raised by Curd-CRM197 
and 15-mer-CRM197 oligosaccharide immunization. These 
antibodies protected mice against lethal infection by Candida 
albicans. Contrariwise, immunization with the 1,6-branched-
17-mer CRM197 oligosaccharide elicited both anti-β-(1,6) and 
anti-β-(1,3) glucan IgG, which was not protective (75).
Conjugation of β-glucan to a carrier protein induces the 
production of antibodies that are protective against major fungal 
pathogens such as Aspergillus spp. and Cryptococcus spp., in 
addition to Candida spp. Growth-inhibitory β-glucan-specific 
antibodies combined with a protein, such as Als3 or Hyr1, could 
enhance the magnitude of protective antibodies as well as reduce 
the chances of Candida albicans immune evasion (76). The impor-
tance of a multivalent vaccine in comparison with the univalent 
anti-β-glucan-specific antibodies (42) was further evaluated by 
using mixed pALS with curdlan for protective immunization. 
Mice were challenged 3  weeks later i.v., with a high dose of 
Candida albicans. Immunization with curdlan alone was not 
sufficient for protection but the combination with pALS greatly 
increased the number of mice protected from fatal systemic 
candidiasis. The enhanced survival upon immunization with 
pALS plus curdlan correlated with the induction of pALS-specific 
IL-17A-producing CD4+ T cells. Data show therefore that pALS-
specific Th17 lymphocytes do protect mice from candidiasis (71).
On Table  1, we summarize the linear peptides carrying 
epitopes potentially effective in antifungal vaccine development.
PAN-FUNGAL vACCiNeS
Recent studies showed that attenuated Blastomyces dermatitidis 
conferred protective effects by T-cell recognition of an unknown 
but conserved antigen [reviewed in Ref. (42)]. Wüthrich et al. using 
transgenic CD4+ T cells identified an amino acid determinant 
within chaperone calnexin that is conserved across ascomycetes 
(77). Calnexin, an ER protein, localizes to the surface of yeast, 
hyphae, and spores (77). Infection with dimorphic or opportun-
istic fungi induces calnexin-specific CD4+ T cells (77). Vaccine 
of calnexin in glucan particles elicited calnexin-specific CD4+ T 
cells and resistance to infection by B. dermatitidis, H. capsulatum, 
Pseudogymnoascus (Geomyces) destructans, Fonsecaea pedrosoi, 
and A. fumigatus (77). Authors investigated regions of conserved 
sequences, which represent shared epitopes recognized by the 
1807-T cell receptor. Using an algorithm that predicts six regions 
of overlapping peptide and a second algorithm developed by 
Marc Jenkins refined the analysis (77). Peptides of 13-mer were 
synthesized, representing 10 predicted epitopes, and they were 
tested for binding to the 1807-T cell receptor. The peptide #1 
(LVVKNPAAHHAIS) activated naive 1807-T cells as measured 
by their reduced expression of CD62L, increased expression of 
CD44, and stimulated production of IFN-γ. None of the other 
calnexin peptides induced IFN-γ production by 1807-T cells 
(77). To investigate the biological relevance of peptide #1 in 
medically important fungi with conserved calnexin sequences, 
naïve 1807-T cells were transferred into mice before infection or 
vaccination with these fungi (77). One week later, activation of 
1807 and endogenous Ag-specific CD4+ T cells using calnexin 
peptide-MHC class II tetramer were analyzed. B. dermatitidis, 
A. fumigatus, H. capsulatum, Coccidioides posadasii, F. pedrosoi, 
and Pseudogymnoascus (Geomyces) destructans expanded and 
activated 1807 and tetramer-positive CD4+ T cells in vivo. Fungi 
that did not trigger expansion of tetramer-positive CD4+ T 
cells included Candida albicans, Cryptococcus neoformans, and 
Pneumocystis jiroveci, and any tetramer-positive CD8+ T cells 
detected in vaccinated mice (77). Vaccination with calnexin 
formulated in glucan particles or Adjuplex induces protective 
immunity against lethal, pulmonary fungal infection with B. 
TABLe 1 | Linear peptide sequences with potential use as vaccine components.
Fungi 
(reference)
Name of antigen and linear 
peptide sequencie
immune 
cell
Animal model 
delivery 
adjuvancy
Results
Paracoccidioides 
brasiliensis (38, 
46, 52, 54)
P10 CD4+ 
Th1 cell
BALB/c mice/
CFA, alumen, 
CL, flagellin, 
DC, DNA 
plasmid
Protection against i.t. challenge, reduction of fungal burden, efficacy of DNA 
vaccineQTLIAIHTLAIRYAN
Coccidioides 
spp. (59)
Antigen 2 (Ag2)/Pra CD4+ 
Th1 cell
C57BL/6 mice/
CpG ODN
Elicit T-cell response in mice immunized with rAg2/Pra; IFN-γ ELISPOT
1P6: TRLTDFKCHCSKPELPGQIT; 
1P7: HCSKPELPGQITPCVEEACP; 
1P12: PIDIPPVDTTAAPE-PSETAE; 
1P13: TTAAPEPSETAEPTAEPTEE; 
1P15: PTEEPTAEPTAEPTAEPTHE; 
1P16: PTAEPTAEPTHEPTEEPTAV
Coccidioides 
spp. (59)
PrP2 CD4+ 
Th1 cell
C57BL/6 mice/
CpG ODN
Elicit T-cell response in mice immunized with rPrP2; IFN-γ ELISPOT
2P6: EKLTDFKCHCAKPELPGKIT; 
2P13: 
DTRTPTQPPSTSPSAPQPTA; 
2P14: 
PSTSPSAPQPTACI-PKRRRA
Coccidioides 
spp. (60)
Predicted T-cell epitopes Pep1 CD4+ T 
cells
HLA-DR4 
C57BL/6 mice/
CpG ODN
Elicit T-cell response in mice immunized with rEBV; IFN-γ ELISPOT
P1: MRNSILLAATVLLGCTSAKVHL; 
P2: HVRALGQKYFGSLPSSQQQTV
Coccidioides 
spp. (60)
Predicted T-cell epitopes Amn1 CD4+ T 
cells
HLA-DR4 
C57BL/6 mice/
CpG ODN
Elicit T-cell response in mice immunized with rEBV; IFN-γ ELISPOT
P10: PAKVDVLLAQSLKLADVLKF; 
P11: NGLATTGTLVLEWTRLSDIT
Coccidioides 
spp. (60)
Predicted T-cell epitopes 
phospholipidase B (Plb)
None HLA-DR4 
C57BL/6 mice/
CpG ODN
Failed to elicit T-cell response from mice immunized with rEBV; IFN-γ ELISPOT
P6: TPLVVYIPNYPYTTWSNIST
Coccidioides 
spp. (60)
Recombinant epitope-based 
vaccine rEBV
CD4+ 
Th1, Th2 
and Th17 
cells
HLA-DR4 
C57BL/6 mice/
CpG ODN or 
GPs plus OVA 
complex
 (a) In vitro T-cell response in mice immunized with rEBV; IFN-γ ELISPOT.
 (b) rEBV + CpG ODN and i.n. challenge: reduction of lung CFU but not 
significant survival.
 (c) rEBV + GPs: 10-fold-higher T-cell response with Pep1-P1 and significant 
enhanced survival.
Include the five selected epitope 
peptides (Pep1, Amn1 and Plb), 
N-terminal leader peptides and 
glycine/proline spacer sequences 
(CPGPG)
Histoplasma 
capsulatum (64)
CDR3 fragment Vβ 
8.1/8.2+ 
T cells
C57BL/6 
and athymic 
nude mice/
TCR α/β–/– and 
IFN-γ–/– mice
 (a) rHsp60 or fragment 3 (F3) confers protection after i.n. challenge.
 (b) Depletion of Vβ 8.1/8.2+ T cells from immunized rHsp60 mice abolish the 
protection to lethal and sublethal challenges.
DGGQG
Aspergillus spp. 
(68, 78)
Asp f3 T cell CF-1 mice/
TiterMax
 (a) rASP f3 confer protection to corticosteroid immunosuppressed CF-1 mice 
against i.n. infection with conidia.
 (b) T-cell proliferation to rAsp f3 variants and trypsin-derived peptides (B12 and 
C3) in immunized CF-1 mice.
B12: PGAFTPVCSAR, C3: 
HVPEYIEKLPEIR
Aspergillus spp. 
(68, 70)
Asp f3 B and T 
cells
CF-1 mice/
TiterMax
 (a) CD4+ T cells are required for rAsp f3 vaccine protection.
 (b) Proliferation of T cells from rAsp f3-vaccinated mice and tested by 
luminometric ATP cell titer quantification in positively selected T cells after 
stimulation.
 (c) P4: VCSARHVPEYIEKLPEIRAK IgG titers were elevated only in the surviving 
vaccinated and Aspergillus fumigatus challenged mice.
P4: VCSARHVPEYIEKLPEIRAK; 
P5: 
EIRAKGVDVVAVLAYNDAYVVCSAR
Candida albicans 
(71)
pALS (ALS1, ALS3) CD4+ 
Th17 
cell
C57BL/6 and 
JHT mice/IFA 
mixed with 
curdlan or CpG
 (a) Peptide-loaded MHCII complex from DC1940 cells isolated and sequenced 
by liquid chromatography coupled to MS/MS.
 (b) Mice immunized with pALS mixed with IFA plus curdlan and i.v. infected with 
Candida albicans protected from fatal systemic disease.
 (c) pALS is recognized by human memory T cells.
KGLNDwNYPvSSeSFS(Y)(T)
(Continued)
8
Travassos and Taborda Peptide Vaccine against Fungal Infection
Frontiers in Immunology | www.frontiersin.org March 2017 | Volume 8 | Article 224
Fungi 
(reference)
Name of antigen and linear 
peptide sequencie
immune 
cell
Animal model 
delivery 
adjuvancy
Results
Candida albicans 
(72)
Hybrid phage displaying epitope B and T 
cells
BALB/c mice/
TE buffer or 
CFA
 (a) Decreased colonization of Candida albicans in kidneys and spleens from mice 
immunized with hybrid phage (TE) or rSap2 (CFA).
 (b) Mice immunized with hybrid phage (TE) or rSap2 (CFA) prolong survival 
against Candida albicans infection.
SLAQVKYTSASSI
Recombinant Sap2 (rSap2)
Pan fungal (77) Calnexin peptide #1 CD4+ Th1 
and Th17 
cells
C57BL/6/
GP-MSA and 
yeast RNA; LPS
 (a) Calnexin (ER protein) has Blastomyces dermatitidis, H. capsulatum, 
Coccidioides posadasii, and Paracoccidioides brasiliensis conserved regions.
 (b) Immunized mice with rCalnexin formulated in GP reduced lung and spleen 
CFU in mice infected with B. dermatitidis or Coccidioides posadasii and 
prolonged survival.
 (c) Soluble calnexin peptide #1 plus LPS delivery by i.v. route improved 
expansion of calnexin-specific T cells.
LVVKNPAAHHAIS
Recombinant calnexin (rCalnexin)
CFA, complete Freund adjuvant; IFA, incomplete Freund adjuvant; CL, cationic lipid; DC, dendritic cells; CpG ODN, synthetic oligodeoxynucleotide containing unmethylated CpG 
dinucleotides; i.t., intratracheal; i.n., intransal; i.v., intravenous; rEBV, bacterium-expressed recombinant epitope-based vaccine; GPs, yeast cell wall-derived glucan particles; GMP, 
glucan mannan particles; CFU, colony forming unit; OVA, chicken ovalbumin; MSA, mouse serum albumin.
TABLe 1 | Continued
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dermatitidis and Coccidioides posadasii. Fungal burdens were 
reduced 10-fold in lung and spleen samples (77).
FiNAL ReMARKS
Albeit most single- or pan-antifungal vaccine in development 
focus on protein/peptide, live-attenuated fungi, immune stimu-
latory adjuvants, antigens presented by DCs, combination of 
polysaccharide with protein where polysaccharide acts as a car-
rier or as a mixing adjuvant, and on passive immunotherapy, the 
synthesis of linear oligosaccharides of β-glucan becomes also an 
alternative to a pan-fungal vaccine.
Liao et al. (78) developed a series of synthetic β-glucan oli-
gosaccharides coupled to keyhole limpet hemocyanin (KLH) to 
generate glycoconjugates that contained structurally well-defined 
carbohydrate antigens. The authors have demonstrated, using a 
mouse model, that the conjugate of KLH and octa-β-glucan can 
elicit protective immune responses against Candida albicans (78).
Although short peptides carrying epitopes mediating immune 
responses may display remarkable activities, even acting as 
antigens and immunomodulatory molecules, it seems that 
multivalent vaccines may be superior to univalent ones, thus 
supporting Cassone’s views on Candida albicans vaccines (76). 
Development of an immune response against “multiple unrelated 
virulence traits” will probably be “a better approach.”
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